Targeted therapies for previously treated advanced or metastatic renal cell carcinoma: systematic review and network meta-analysis.

ABSTRACT:

Objective

To compare the effectiveness and safety of treatments for advanced or metastatic renal cell carcinoma (amRCC) after treatment with vascular endothelial growth factor (VEGF)-targeted treatment.

Design

Systematic review and network meta-analysis of randomised controlled trials (RCTs) and comparative observational studies. MEDLINE, EMBASE and Cochrane Library were searched up to January 2018.

Participants

People with amRCC requiring treatment after VEGF-targeted treatment.

Interventions

Axitinib, cabozantinib, everolimus, lenvatinib with everolimus, nivolumab, sorafenib and best supportive care (BSC).

Outcomes

Primary outcomes were overall survival (OS) and progression-free survival (PFS); secondary outcomes were objective response rate (ORR), adv

SUBMITTER: Karner C 

PROVIDER: S-EPMC6429896 | biostudies-literature | 2019 Mar

REPOSITORIES: biostudies-literature